Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Hangzhou Adicon Clinical Laboratories, Inc. is a Chinese private company located in Hangzhou that provides healthcare testing services.

CSL Behring is a global leader in the plasma protein biotherapeutics industry. They research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of Their therapies rely on them for their quality of life and, in many cases, for life itself. Their commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything They do. Whether They are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, They are first and foremost focused on fulfilling Their customers’ needs.

The Jewish General Hospital (JGH; French: Hôpital général juif), known officially as the Sir Mortimer B. Davis Jewish General Hospital (French: Hôpital général juif Sir Mortimer B. Davis) since 1978, is an acute-care teaching hospital in Montreal, Quebec, Canada. Affiliated with McGill University, it has 637 beds.

Hunan Jiahui Biotechnology Co., Ltd., established on 2009-05-22, Business scope includes biotechnology consulting,communication service,development services,transfer service;Research on Assisted Reproduction and Genetic Eugenics;Medical Research and Experimental Development;Organization of training events;medical information,Technical Advisory Services;research and development,Incubation and Transformation;Hospital Operations and Management;Reproductive Health and Infertility Specialist(limited branch);Obstetrics and Gynecology(limited branch);Pediatrics(limited branch);internal medicine(limited branch);surgery(limited branch);ENT(limited branch);Oncology(limited branch);Gynecology(limited branch);medical imaging(limited branch);Anesthesiology(limited branch);Pathology(limited branch);Emergency Medicine(limited branch);Preventive health care(limited branch);Department of Rehabilitation Medicine(limited branch);Internet hospital(limited branch);Health Checkup Service(limited branch);Digital Pathology Remote Diagnosis(limited branch);telemedicine(limited branch);Video remote monitoring(limited branch);Teleconsultation(limited branch);Remote case discussion(limited branch);remote clinic(limited branch);Internal medicine diagnosis and treatment service(limited branch);Surgical services(limited branch);Gynecological Clinic Services(limited branch);Preventive health department diagnosis and treatment services(limited branch);Medical Imaging Department Diagnosis and Treatment Services(limited branch);Clinical Laboratory Services(limited branch);clinical body fluids(limited branch);Clinical Hematology(limited branch);clinical microbiology major(limited branch);clinical chemistry laboratory(limited branch);clinical immunology major(limited branch);clinical serology major(limited branch);Clinical Cytomolecular Genetics Major(limited branch).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Do not engage in unauthorizedP2Ponline loan,Equity crowdfunding,internet insurance,Asset management and cross-border finance,Third party payment,virtual currency transaction,ICO,Internet financial services such as illegal foreign exchange)

The Carlos III Health Institute (Spanish: Instituto de Salud Carlos III; ISCIII) is a Spanish public health research institute, legally constituted as a public research agency (Spanish: Organismo Público de Investigación), a type of quasi-autonomous entity under Spanish law. The agency is integrated in the Department of Science and Innovation, although it also reports to the Department of Health in the institute's activities relating health, healthcare and its planning.

bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.